Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection.


Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
02 2019
Historique:
received: 06 11 2017
revised: 29 08 2018
accepted: 27 09 2018
pubmed: 7 11 2018
medline: 30 6 2019
entrez: 7 11 2018
Statut: ppublish

Résumé

Central nervous system diseases are not currently diagnosed based on knowledge of biological mechanisms underlying their symptoms. Greater understanding may be offered through an agnostic approach to traditional disease categories, where learning more about shared biological mechanisms across conditions could potentially reclassify sub-groups of patients to allow realisation of more effective treatments. This review represents the output of the collaborative group "PRISM", tasked with considering assay choices for assessment of attention and working memory in a transdiagnostic cohort of Alzheimer's disease and schizophrenia patients exhibiting symptomatic spectra of social withdrawal. A multidimensional analysis of this nature has not been previously attempted. Nominated assays (continuous performance test III, attention network test, digit symbol substitution, N-back, complex span, spatial navigation in a virtual environment) reflected a necessary compromise between the need for broad assessment of the neuropsychological constructs in question with several pragmatic criteria: patient burden, compatibility with neurophysiologic measures and availability of preclinical homologues.

Identifiants

pubmed: 30399355
pii: S0149-7634(17)30815-1
doi: 10.1016/j.neubiorev.2018.09.025
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

47-69

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Gary Gilmour (G)

Translational Neuroscience, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. Electronic address: gilmour_gary@lilly.com.

Stefano Porcelli (S)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.

Valérie Bertaina-Anglade (V)

Biotrial, 7-9 rue Jean-Louis Bertrand, CS, 34246, 35042 Rennes Cedex, France.

Estibaliz Arce (E)

Early Clinical Development, Worldwide Research and Development, Pfizer Inc., United States.

Juergen Dukart (J)

F. Hoffmann-La Roche, pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.

Anja Hayen (A)

P1vital Ltd., Wallingford, Oxfordshire, UK.

Antonio Lobo (A)

Department of Medicine and Psychiatry, University of Zaragoza, Zaragoza, Spain; Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.

Raul Lopez-Anton (R)

Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Psychology and Sociology Department, University of Zaragoza, Zaragoza, Spain.

Emilio Merlo Pich (E)

CNS Therapeutic Area Unit, Takeda Development Centre Europe, London, England.

Darrel J Pemberton (DJ)

Janssen Research and Development, Beerse, Belgium.

Martha N Havenith (MN)

Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.

Jeffrey C Glennon (JC)

Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.

Brian T Harel (BT)

Early Clinical Development, Worldwide Research and Development, Pfizer Inc., United States.

Gerard Dawson (G)

P1vital Ltd., Wallingford, Oxfordshire, UK.

Hugh Marston (H)

Translational Neuroscience, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK.

Rouba Kozak (R)

Early Clinical Development, Worldwide Research and Development, Pfizer Inc., United States.

Alessandro Serretti (A)

Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH